d837c3e6-ef78-42a0-8a39-c57d48bc7c3a
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 59
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- BILE_ACID_METABOLISM+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.320
- DNA_REPAIR+0.310
- PEROXISOME+0.310
- MYC_TARGETS_V1+0.300
- XENOBIOTIC_METABOLISM+0.270
- GLYCOLYSIS+0.250
- ADIPOGENESIS+0.230
- UV_RESPONSE_UP+0.230
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.460
- MITOTIC_SPINDLE-0.330
- TNFA_SIGNALING_VIA_NFKB-0.260
- UV_RESPONSE_DN-0.260
- APICAL_SURFACE-0.220
- INTERFERON_ALPHA_RESPONSE-0.190
- ANGIOGENESIS-0.180
- KRAS_SIGNALING_UP-0.130
- INFLAMMATORY_RESPONSE-0.120
- INTERFERON_GAMMA_RESPONSE-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | d22c9285-50cf-4724-9f81-606fb54c00fc | — | — | 0.860 |
| 2 | f844415e-ca2a-4837-b050-06775fdb2ed5 | — | — | 0.831 |
| 3 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.789 |
| 4 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.789 |
| 5 | 0acddbbc-6b74-4fdd-903d-f5ec9bfd8514 | — | — | 0.771 |
| 6 | TCGA-66-2778-01A-02R-0851-07 | — | cohortSQ1 | 0.760 |
| 7 | 4613d81b-e9ba-4c36-96a5-d7c9667b83ec | — | — | 0.758 |
| 8 | MNG785 | — | — | 0.753 |
| 9 | 2d83a9e6-da2d-47e1-b2e7-4b07b108f7bd | — | — | 0.751 |
| 10 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.747 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| BILE_ACID_METABOLISM | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| PEROXISOME | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.270 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.230 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.160 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.130 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.120 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.060 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.050 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.040 | Inavolisib | — uncovered |